Trigger primary analysis for IGNYTE anti-PD-1 failed melanoma cohort
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2021
- Due
- 30 Jun 2023
- Delivered
- June 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the primary analysis is expected to be triggered in mid-year 2023”
What we found
Evidence strength A What the grades mean
The company announced in June 2024 that the primary data analysis for the IGNYTE anti-PD-1 failed melanoma cohort had been completed, which occurred after the mid-2023 target.
-
A Replimune Group, Inc. 10-Q filed 2024-08-08
“the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial, that, as reported in June 2024, had positive topline primary data analysis by independent central review.” ✓ confirmed on the page
Market reaction: the shares moved +1.0% against the S&P 500 over the three sessions around the disclosure (7 Aug 2024 to 12 Aug 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Trigger
- Deliverable
- Primary analysis trigger for IGNYTE anti-PD-1 failed melanoma cohort
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REPL-002641 · Corrections policy